Dwight Moxie
CIK 1803375 · CLO & GC · last filed 2025-02-06
Dwight Moxie is a CLO & GC who has filed 19 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for RVNC, was dated Feb 6, 2025. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
19
-$2.33M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) Delisted | CLO & GC | 95,979 | $3.65 | $350.3K | -$2.33M | 19 | 2025-02-06 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −143,794 | -$174.5K | EDGAR |
| 2025-02-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +5,979 | $0 | EDGAR |
| 2024-03-19 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −11,394 | -$58.3K | EDGAR |
| 2024-03-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +15,143 | $0 | EDGAR |
| 2024-02-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +90,000 | $0 | EDGAR |
| 2023-09-07 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −34,853 | -$612.6K | EDGAR |
| 2023-08-15 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +9,754 | -$181.4K | EDGAR |
| 2023-05-16 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +20,948 | -$739.3K | EDGAR |
| 2023-03-17 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −7,330 | -$224.7K | EDGAR |
| 2023-03-09 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +23,853 | -$584.2K | EDGAR |